Latest news with #AbuDhabiGlobalHealthcareWeek2025
Al Etihad
17-04-2025
- Health
- Al Etihad
DoH partners with Gilead Sciences to propel healthcare innovation, cell therapy advancement
17 Apr 2025 18:59 ABU DHABI (ALETIHAD)As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW).As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the the presence of Dr. Noura Khamis Al Ghaithi, Under-Secretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said, 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences, commented, 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.'
Zawya
17-04-2025
- Health
- Zawya
Cleveland Clinic Abu Dhabi unveils new technologies to support cancer patients
Cleveland Clinic Abu Dhabi has introduced a series of new technologies and initiatives aimed at enhancing cancer patient care, as part of its participation in Abu Dhabi Global Healthcare Week 2025. In statements to the Emirates News Agency (WAM), Dr. Stephen R. Grobmyer, Institute Chair of the Oncology Institute at Cleveland Clinic Abu Dhabi - Fatima bint Mubarak Centre, said that while the hospital is showcasing the latest cancer treatments, the main focus is on supportive care, especially during the most challenging phases of treatment. 'Our goal is not only to provide medical care, but to deliver a holistic, human-centred experience that respects patients' needs and supports them throughout their health journey,' he said. As part of this approach, the hospital launched an innovative programme using the BioButton wearable device, now in use with cancer patients at the Fatima bint Mubarak Centre. The technology enables remote monitoring after patients are discharged, helping detect symptoms and complications early and allowing for timely intervention. This, Grobmyer said, improves patient safety and comfort during recovery. The hospital also introduced solutions to reduce the side effects of chemotherapy, one of the most pressing challenges faced by patients. These include a scientifically validated cooling cap worn during chemotherapy to significantly reduce hair loss—a side effect that often has psychological impacts. In addition, a hand-cooling system is being used with certain treatments to help prevent nerve damage and chemotherapy-induced neuropathy.
Zawya
17-04-2025
- Health
- Zawya
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement
This collaboration supports Abu Dhabi's commitment to building a resilient healthcare ecosystem that prioritises preventative, personalised and comprehensive care Abu Dhabi, UAE: As part of its commitment to advance healthcare innovation, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has announced a dual Memoranda of Understanding (MoU) with Gilead Sciences, a global biopharmaceutical company, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). As part of the agreement, both parties aim to broaden collaboration in clinical research, advanced therapies and healthcare accessibility, while also enhancing treatment options and driving cutting-edge medical innovation in the emirate In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), the MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH) and Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences. Reflecting Abu Dhabi's standing as a global leader in healthcare innovation, these agreements are set to propel the emirate to the forefront of medical research and development. By focusing on advancements in virology and cell therapies, the partnership aims to expand access to pioneering treatments and enhance healthcare outcomes for communities. This strategic collaboration reinforces Abu Dhabi's commitment to integrating state-of-the-art medical technologies and research capabilities, thus ensuring the emirate remains a hub for healthcare excellence and a model for world-class healthcare practices. Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: 'Research and development are crucial for fostering innovation and ensuring the sustainable advancement of the health and life sciences ecosystem. This commitment ultimately supports proactive and holistic care for our communities. In alignment with Abu Dhabi's vision to establish one of the world's smartest healthcare systems, we are dedicated to empowering our community with the tools necessary for maintaining healthy populations for generations to come. Furthermore, we continue to forge strategic partnerships that enhance our capacity to deliver best-in-class care to community members in the emirate and beyond.' Vitor Papao, General Manager, Middle East, Russia, Turkiye at Gilead Sciences commented: 'These MoUs reaffirm Gilead and Kite's commitment to healthcare innovation and underscore our l contribution to the healthcare ecosystem in Abu Dhabi. By collaborating with leading institutions, we are proud to support Abu Dhabi's vision of becoming a leader in medical research and advanced therapeutics backed by a robust knowledge economy. This collaboration aligns with national efforts to strengthen healthcare systems, advance medical research, and expand access to life-changing treatments, such as our innovative CAR T-cell therapies.' ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. For more information, visit About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. For further information on DOH, visit and follow on X, Instagram, Facebook, LinkedIn and YouTube. For media inquiries, please contact: Mariam Al Marzooqi, msalmarzooqi@ About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead acquired Kite in 2017. About Kite Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on achieving cures with cell therapy. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply and commercial product manufacturing.
Al Etihad
17-04-2025
- Health
- Al Etihad
Oliver Wyman backs Abu Dhabi's vision to become global healthcare leader
17 Apr 2025 14:51 ABU DHABI (WAM)Global consulting firm Oliver Wyman, the knowledge partner of Abu Dhabi Global Healthcare Week 2025, has reiterated its support for Abu Dhabi's ambition to establish itself as a leading global hub for healthcare and life sciences by promoting innovation, expanding international collaboration, and sharing expert statements to the Emirates News Agency (WAM), Sumit Sharma, Partner and Head of Health and Life Sciences in India, the Middle East, and Africa, said that Abu Dhabi has positioned itself as a rising global player in healthcare. He emphasised the need to build on this momentum by cultivating an ecosystem that encourages innovation and described Abu Dhabi Global Healthcare Week as a key platform that brings together global experts and decision-makers to explore investment opportunities and forge new Wyman will play an active role at the event by organising and participating in expert panels and contributing to strategic discussions aimed at advancing healthcare quality and also announced the launch of a new research paper during the week, which will focus on two priority areas: faster access to medicines and mental health. The paper aligns with Abu Dhabi's broader goals to enhance quality of life and promote long-term healthcare sustainability. He underlined the importance of the study, which is being developed in collaboration with local regulators, as a step toward creating a global healthcare model that puts human well-being at the centre and is driven by innovation and knowledge.
Zawya
16-04-2025
- Health
- Zawya
DoH and ADIO partner with unilabs to establish advanced analytical laboratory for clinical research
By working hand-in-hand with ADIO and Unilabs, the Department remains dedicated to providing innovative treatments and breakthrough solutions in the UAE and around the world Abu Dhabi, UAE: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and the Abu Dhabi Investment Office (ADIO) have signed a Memorandum of Understanding (MoU) with Unilabs Pharma Solutions, a subsidiary of leading international provider of diagnostic services Unilabs, on the sidelines of Abu Dhabi Global Healthcare Week 2025 (ADGHW). Under the agreement, the parties aim to develop a state-of-the-art analytical laboratory as part of Abu Dhabi's recently launched Health, Endurance, Longevity, and Medicine (HELM) cluster, a pioneering hub for biotechnology, MedTech and digital health innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of Department of Health – Abu Dhabi (DoH) and Carsten Hojlund, Group Chief Financial Officer at Unilabs. The MoU was signed by Dr. Asma Ibrahim Al Mannaei, Executive Director of Health Life Sciences Sector at DoH, Mohammed Daoud, Cluster General Manager of Unilabs Middle East and Dr. Fatma Al Mulla, Head of the Health, Endurance, Longevity, and Medicine cluster at ADIO. Under the MoU, the parties seek to drive advancements in drug development, clinical trials and screening, aligning with DoH's efforts to position the Emirate as a global life sciences hub and an incubator for responsible healthcare innovation. Through working hand in hand with Unilabs and ADIO, the Department remains dedicated to providing innovative treatments and breakthrough solutions in the UAE and around the world. Dr. Asma Ibrahim Al Mannaei, Executive Director of Health Life Sciences Sector at the Department of Health – Abu Dhabi (DoH), said: " In Abu Dhabi, we are strategically advancing health and life sciences through driving investment in transformative technologies, diagnostics and treatments to elevate healthcare outcomes while fostering sustainable economic growth. Working alongside prestigious partners such as the Abu Dhabi Investment Office and Unilabs Pharma Solutions, DoH remains steadfast in our commitment to positioning the Emirate as a leading destination for life science, accelerating innovation and expanding access to cutting-edge health services and treatment for communities locally and globally. This state-of-the-art analytical laboratory exemplifies the Department's proactive vision to establish a dynamic, future-ready healthcare ecosystem that anticipates challenges, embraces adaptability and prioritises the evolving needs of all communities, ensuring a resilient, healthier and innovation-driven tomorrow.' By leveraging the combined expertise of all three partners, the analytical laboratory's advanced technology and operational capabilities will be deployed through a potential greenfield project, enhancing the economic value of high-impact intellectual property. Further, support mechanisms will be explored to maximise the initiative's long-term economic benefits, including high-value job creation, supply chain localisation and increased investment in cutting-edge healthcare infrastructure. Dr. Fatma Al Mulla, Head of the Health, Endurance, Longevity, and Medicine Cluster at the Abu Dhabi Investment Office (ADIO), stated: "This partnership is a clear example of how we are embedding advanced capabilities across the life sciences value chain, creating a launchpad for innovation that begins with research and extends through to real-world impact. By investing in early-stage analytical infrastructure, Abu Dhabi is not only strengthening its role in the global life sciences landscape but is also laying the foundation for impactful intellectual property generation, high-value job creation and knowledge transfer. This initiative exemplifies the cluster's ambition to ensure that healthcare innovation contributes directly to economic acceleration, technological advancement and the development of a sustainable, knowledge-based economy —one that is anchored in Abu Dhabi, and connected to the world.' Mohammed Daoud, Cluster General Manager of Unilabs Middle East:"We are proud to be part of this strategic project and look forward to exploring collaboration opportunities. With our cutting-edge pharmaceutical analysis technologies, internationally accredited laboratory tests, and strong capacity to train local talent, Unilabs is the ideal partner to help strengthen integration with the existing healthcare system. Abu Dhabi offers an exceptional environment for such transformative initiatives, thanks to the tireless commitment of government entities and their continuous support for innovation. We are excited about the potential to establish an advanced analytical centre in Abu Dhabi. The emirate boasts a state-of-the-art infrastructure and a clear vision for growth in the healthcare and innovation sectors. We very much look forward to exploring mutually beneficial ways to bring our expertise and support Abu Dhabi's efforts to become a major hub for drug development in the region. This centre would be Unilabs Pharma Solutions' first investment in pharmaceutical solutions in the Middle East." ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care. Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being. ADGHW 2025 offers complimentary visitor passes that grant access to the event's Start Up Zone, live stage sessions and exhibition hall featuring 150 global leaders in health. About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual. About the Abu Dhabi Investment Office (ADIO): The Abu Dhabi Investment Office (ADIO) is the government vehicle responsible for accelerating Abu Dhabi's growth and enabling the emirate's economic transformation. Through comprehensive support services, ADIO enables both local and foreign investors to shape industries of the future set to transform liveability, technology, resources and value-added services. Initiatives focused on regional tourism and retail development, as well as public-private partnerships, ensure that community well-being is at the centre of Abu Dhabi's economic transformation. With a robust network of investors, strong collaboration with key stakeholders and a global presence, ADIO is committed to empowering those who invest with Abu Dhabi to make a lasting global impact. About Unilabs: Unilabs is a leading international provider of diagnostic services offering a complete range of laboratory, pathology, genetics and imaging services to patients across four continents. With over 13,000 people in 14 markets, Unilabs invests heavily in technology, equipment, and people – using digital technologies in its state-of-the-art laboratories and imaging institutes – to improve the lives of close to 100 million people every year.
